Shandong Boan Biotech Co Ltd (6955) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of Shandong Boan Biotech Co Ltd HK$0.38, price HK$2.95, upside -87.0%, quality 25 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Shandong Boan Biotech Co Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
45‑month range HK$2.44 – HK$24.55 · fair‑value band HK$0.2720 – HK$0.5015 · the HK$2.95 price screens above the HK$0.3825 fair value. Dashed = 300-day average. As of Sep 24, 2026.
Follow Shandong Boan Biotech Co in your weekly email
Every Wednesday you see whether Shandong Boan Biotech Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Shandong Boan Biotechnology Co., Ltd., a biopharmaceutical company, develops, manufactures, and markets biologics in Mainland China.
Show more
Shandong Boan Biotechnology Co., Ltd., a biopharmaceutical company, develops, manufactures, and markets biologics in Mainland China. The company offers Boyounuo (BA1101), an anti-VEGF humanized monoclonal antibody injection for mCRC, advanced metastatic or recurrent non-small cell lung cancer, recurrent glioblastoma, epithelial ovarian, fallopian tube, primary peritoneal cancer, cervical cancer, and hepatocellular carcinoma indications; Boyoubei (BA6101), a human immunoglobulin G2 monoclonal antibody of the RANK ligand for the treatment of postmenopausal and male osteoporosis; and Boluojia (BA1102), a fully human IgG2 anti-RANKL monoclonal antibody to treat bone metastases from solid tumors, and giant cell tumor of bone. It also develops BA5101, a long-acting glucagon-like peptide-1 receptor agonist intended for glycemic control in adults with type 2 diabetes; BA9101, a recombinant human vascular endothelial growth factor receptor antibody fusion protein ophthalmic injection; BA1104, a monoclonal antibody in Phase 3 clinical trial that can enhance the immune response of T cells against tumors by preventing the programmed cell death 1 receptor; BA2101, a long-acting human monoclonal antibody of the IgG4 subtype in Phase 1b/2 trial that targets interleukin-4 receptor subunit a; BA1106, a non-IL-2 blocking anti-CD25 antibody in Phase 1b/2 trial; BA1301, an ADC candidate in Phase 1b/2 trial that targets Claudin 18.2; BA1202, a bi-specific antibody drug in Phase 1a trial that targets CEA/CD3; and BA1302, a CD228-directed ADC in Phase 1a trial. It has an agreement with the Zencore Biologics Co., Ltd. to use its stable cell line development platform non-exclusively, BA-HIEXcell for the development of antibodies and therapeutic proteins. The company was founded in 2013 and is headquartered in Yantai, China. Shandong Boan Biotechnology Co., Ltd. is a subsidiary of Shandong Luye Pharmaceutical Co., Ltd.
Stock analysis
Shandong Boan Biotech Co Ltd (6955) currently trades at HK$2.95, while our model-based Fair Value estimate is HK$0.3825, implying the stock looks roughly 671.0% overvalued today.
Show more
Valuation
Bull case: the Asset-Based group reads highest at a median of HK$2.95 per share, and 1 of the 14 models we run sit above the HK$2.95 price.
Bear case: the Multiples group reads lowest at HK$0.2500, and 13 of the 14 models stay below the price. Evidence for this calculation is low.
Scenario range: HK$0.2720 (bear) to HK$0.5015 (bull), the price of HK$2.95 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 25/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Shandong Boan Biotech Co Ltd reported revenue of 785M CNY in FY2025 versus 159M CNY in FY2021, a compound +49.1%/yr. Reported net income was 7.1M CNY in FY2025.
Key figures
Market cap HK$2.9B (≈ $374M) · P/E ratio 471.0 · P/S ratio 4.29 · EPS (TTM) HK$0.0400 · Net margin 0.9% · Return on equity 0.3% · Return on assets (EBIT) −4.9% · Operating margin −2.1%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (low confidence).
What moves the price
The share trades about 78% below its 52-week high and 21% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −87%, 6955 screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely (HK$0.2000 to HK$4.32). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear HK$0.2720Fair Value HK$0.3825Bull HK$0.5015
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (HK$0.0294 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.42/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+8.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.0%
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−134.7% (2021) → 5.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
Compare Shandong Boan Biotech Co Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 649 stocks
Beats the industry median on 5/12 measures
A mixed picture versus its industry peers.
Valuation
Quality Score25 · Bottom 25%
Fair Value upside−86% · Bottom 25%
Profitability
Return on equity (TTM)0% · Above median
Return on assets1% · Above median
Net margin (TTM)1% · Below median
Operating margin (TTM)−2% · Below median
Growth and dividend
Revenue growth8% · Above median
Balance sheet
Debt / equity0.11× · Above median
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/E (TTM)471.0× · Priciest 25%
P/B0.91× · Cheaper than median
P/S (TTM)3.19× · Cheaper than median
EV/EBITDA19.9× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)39· sector 0
PAST (return on equity)1· sector 0
HEALTH (low debt)94· sector 97
DIVIDEND (yield)0· sector 23
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Shandong Boan Biotech Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/6955
Frequently asked questions
Is Shandong Boan Biotech Co Ltd (6955) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of HK$0.3825 versus a price of HK$2.95, about −87% upside (overvalued).
What is the fair value of 6955?
Our model-based fair value for Shandong Boan Biotech Co Ltd is HK$0.3825 (as of Sep 24, 2026), built from audited fundamentals. The current price: HK$2.95.
What is the quality score of 6955?
Shandong Boan Biotech Co Ltd has a Quality Score of 25/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Shandong Boan Biotech Co Ltd (6955)?
Our model-based price target is the fair value of HK$0.3825 (as of Sep 24, 2026) from 14 valuation models. Cautious scenario HK$0.2720, optimistic scenario HK$0.5015. It is a calculation from audited fundamentals, not an analyst target.
What is the Shandong Boan Biotech Co Ltd stock forecast for 2026?
Our models put fair value at HK$0.3825, about −87% upside versus a price of HK$2.95 (overvalued). Cautious scenario HK$0.2720, optimistic scenario HK$0.5015. The calculation is refreshed regularly with new filings.
What is the revenue of Shandong Boan Biotech Co Ltd (6955)?
Shandong Boan Biotech Co Ltd reported trailing-twelve-month revenue of about 785M CNY (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Shandong Boan Biotech Co Ltd (6955)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Shandong Boan Biotech Co Ltd it is HK$0.3825 per share (as of Sep 24, 2026), against a price of HK$2.95. It is the blended result of 14 valuation models (cash flow, earnings, asset, dividend).
Is Shandong Boan Biotech Co Ltd stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 6955 trades above its calculated fair value: price HK$2.95, fair value HK$0.3825, a gap of about −87% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6955?
No. The price is what the market pays today (HK$2.95); the fair value is what the company's own numbers justify (HK$0.3825). For Shandong Boan Biotech Co Ltd the two are HK$2.57 per share apart. That gap is exactly why we show both numbers side by side.
How much is Shandong Boan Biotech Co Ltd worth?
The market values Shandong Boan Biotech Co Ltd at about HK$2.9B (market capitalisation, as of Sep 24, 2026). Per share that is HK$2.95; our models calculate a fair value of HK$0.3825 per share.
What do the bullish and bearish scenarios say about 6955?
Our models span a range for Shandong Boan Biotech Co Ltd: cautious scenario HK$0.2720, base HK$0.3825, optimistic HK$0.5015 per share (as of Sep 24, 2026, price HK$2.95). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 6955?
Shandong Boan Biotech Co Ltd trades at a price-to-earnings ratio of 471.0 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of HK$0.3825 is built from several models across several years. Other multiples: P/B 0.9, P/S 3.2, EV/EBITDA 19.9.
How solid is the balance sheet of Shandong Boan Biotech Co Ltd (6955)?
Balance-sheet figures for Shandong Boan Biotech Co Ltd (as of Sep 24, 2026): return on equity 0.3%, debt of 0.11 per unit of equity. They feed the Quality Score of 25/100, which measures business quality independently of the share price.
How far is 6955 from its 52-week high?
Shandong Boan Biotech Co Ltd trades at HK$2.95, about 78% below its 52-week high of HK$13.45 and 21% above the low of HK$2.44 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of HK$0.3825 is for.
Which stocks are comparable to Shandong Boan Biotech Co Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Shandong Boan Biotech Co Ltd stock attractive at the current price?
The data as of Sep 24, 2026: price HK$2.95, calculated fair value HK$0.3825 (−87%), Quality Score 25/100, from 14 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 6955 calculated?
We run Shandong Boan Biotech Co Ltd through 14 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of HK$0.3825, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Shandong Boan Biotech Co Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Shandong Boan Biotech Co Ltd (6955)?
The closing price on Sep 24, 2026 was HK$2.95. Our model-based fair value is HK$0.3825, about −87% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Shandong Boan Biotech Co Ltd right now?
The price sits above even our optimistic bull case (HK$0.5015). The favourable scenario is already priced in. Weak quality (25/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (HK$0.2720 to HK$0.5015) leaves room in how you read the outcome.
Key figures of Shandong Boan Biotech Co Ltd
How large is the market capitalisation of Shandong Boan Biotech Co Ltd (6955)?
The market capitalisation of Shandong Boan Biotech Co Ltd is HK$2.9B (≈ $374M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Shandong Boan Biotech Co Ltd (6955)?
The price-to-sales ratio of Shandong Boan Biotech Co Ltd is 4.29 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Shandong Boan Biotech Co Ltd (6955)?
Earnings per share at Shandong Boan Biotech Co Ltd are HK$0.0400 (price ÷ EPS = P/E 471.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Shandong Boan Biotech Co Ltd (6955)?
The net margin of Shandong Boan Biotech Co Ltd is 0.9% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Shandong Boan Biotech Co Ltd (6955)?
The return on equity (ROE) of Shandong Boan Biotech Co Ltd is 0.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Shandong Boan Biotech Co Ltd (6955)?
On an EBIT basis the return on assets of Shandong Boan Biotech Co Ltd is −4.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Shandong Boan Biotech Co Ltd (6955)?
The operating margin of Shandong Boan Biotech Co Ltd is −2.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Shandong Boan Biotech Co Ltd (6955)?
Revenue at Shandong Boan Biotech Co Ltd is growing +7.7% versus a year earlier (3y avg +15.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Shandong Boan Biotech Co Ltd (6955)?
Earnings per share at Shandong Boan Biotech Co Ltd are growing −70.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Shandong Boan Biotech Co Ltd (6955) generate?
The free cash flow of Shandong Boan Biotech Co Ltd is −209M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Shandong Boan Biotech Co Ltd (6955) carry?
The net debt of Shandong Boan Biotech Co Ltd is 480M CNY (fiscal year 2024). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Shandong Boan Biotech Co Ltd in the live analysis
One click puts Shandong Boan Biotech Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
